AbCellera Biologics Inc vs Gogoro Inc — how do they compare? AbCellera Biologics Inc trades at $10.2 (market cap $2.99B), while Gogoro Inc trades at $2.5 (market cap $52.19M). The key difference: AbCellera Biologics Inc is far larger — about 57.3× Gogoro Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | GGR | |
|---|---|---|
Market Cap | $2.99B | $52.19M |
Sector | Health | Technology |
52-Week High | $9.76 | $7.50 |
52-Week Low | $2.78 | $2.55 |
Enterprise Value | $2.58B | $354.63M |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
GGR trades at $2.63, up 1.94% today, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $79.97 million on $281.48 million revenue in 2025, with negative margins and cash flow, though 2026 projections show improvement. Analyst consensus is entirely hold, reflecting caution amid ongoing losses.
Outlook remains challenging with persistent losses and negative cash flow, but low P/S and P/B ratios may attract value investors if operational improvements materialize. Key risks include execution on profitability, competitive pressures, and reliance on future growth initiatives to achieve sustained positive earnings.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →